You are here
- Home
- Therapy Areas
- Oncology/Infection
A Double Blind Randomized Trial of Cediranib versus placebo in patients receiving Paclitaxel/Carboplatin Chemotherapy for the treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
- Disease
- non-small cell lung cancer
- Drug Name
- RECENTIN
- Generic Name
- AZD2171
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- Other
- Start Date
- Feb 4, 2009
- Study Name
- D8483C00002
- Study Id
- D8483C00002
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
